Skip to main content

Vivo Capital Fund VIII, L.P.'s Form 4 filing

Bolt Biotherapeutics, Inc. (BOLT) · filed Nov 22, 2023

Accession no.
0001213900-23-089692
Filed
Nov 22, 2023, 6:51 PM ET
Trade date
Nov 21, 2023
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $3.06K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Vivo Capital Fund VIII, L.P.CIK 000161878810% Owner
Vivo Capital VIII, LLCCIK 000161878910% Owner
Vivo Capital Surplus Fund VIII, L.P.CIK 000162804810% Owner
Vivo Panda Fund, L.P.CIK 000167549010% Owner
Vivo Opportunity, LLCCIK 000172897010% Owner
Vivo Panda, LLCCIK 000184384710% Owner
Vivo Opportunity Fund Holdings, L.P.CIK 000193021410% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 21, 2023Common StockSSaleDisposed−1,707$0.90−$1,536.31,952,302Indirect
Nov 21, 2023Common StockSSaleDisposed−236$0.90−$212.4269,587Indirect
Nov 21, 2023Common StockSSaleDisposed−1,457$0.90−$1,311.3111,662Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)